1. Home
  2. HY vs GYRE Comparison

HY vs GYRE Comparison

Compare HY & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyster-Yale Materials Handling Inc.

HY

Hyster-Yale Materials Handling Inc.

HOLD

Current Price

$31.21

Market Cap

700.0M

Sector

Industrials

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.49

Market Cap

759.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HY
GYRE
Founded
1991
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
700.0M
759.1M
IPO Year
2012
2004

Fundamental Metrics

Financial Performance
Metric
HY
GYRE
Price
$31.21
$7.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
104.8K
108.3K
Earning Date
06-08-2026
06-18-2026
Dividend Yield
4.60%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
$3,769,300,000.00
$275,000.00
Revenue This Year
$1.85
$27.85
Revenue Next Year
$3.80
$0.80
P/E Ratio
N/A
$188.88
Revenue Growth
N/A
N/A
52 Week Low
$26.41
$6.11
52 Week High
$46.87
$11.77

Technical Indicators

Market Signals
Indicator
HY
GYRE
Relative Strength Index (RSI) 32.67 41.80
Support Level $27.62 $7.07
Resistance Level $38.75 $8.25
Average True Range (ATR) 2.20 0.61
MACD -0.91 -0.10
Stochastic Oscillator 0.00 9.65

Price Performance

Historical Comparison
HY
GYRE

About HY Hyster-Yale Materials Handling Inc.

Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: